Literature DB >> 25323420

Optimal strategies for managing fetal growth restriction.

E Hernandez-Andrade1.   

Abstract

Early dating of pregnancy by ultrasound is necessary to establish the adequate fetal growth. Customized or individualized estimation of fetal growth is probably a better option than population based curves to identify fetuses at a higher risk of perinatal complications. Biological maternal markers and placental evaluation might contribute in the identification of fetuses at risk of abnormal growth. There is no specific Doppler pattern of fetal deterioration; however, in early growth restriction it is mainly expressed in the umbilical artery, and in late growth restriction (>34 weeks) in the middle cerebral artery. Abnormal biophysical profile and/or non-stress test can be considered as acute signs of fetal decompensation. Magnetic resonance imaging can provide information of fetuses at risk of abnormal neurodevelopment. Neonatal body composition in low birthweight newborns can be used to identify children at risk of metabolic complications. Gestational age at delivery is the most important parameter associated with perinatal morbidity and mortality; however, waiting until the ductus venosus is severely abnormal might reduce the possibilities of survival of preterm fetuses with abnormal growth.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25323420

Source DB:  PubMed          Journal:  Minerva Ginecol        ISSN: 0026-4784


  2 in total

1.  Third trimester growth restriction patterns: individualized assessment using a fetal growth pathology score.

Authors:  Russell L Deter; Wesley Lee; Haleh Sangi-Haghpeykar; John Kingdom; Roberto Romero
Journal:  J Matern Fetal Neonatal Med       Date:  2017-07-06

2.  Screening for small for gestational age using third-trimester ultrasound markers: protocol for a systematic review and meta-analysis of screening test accuracy.

Authors:  Cédric Gasse; Kim Paquette; Suzanne Demers; Stéphanie Roberge; Emmanuel Bujold; Amélie Boutin
Journal:  Syst Rev       Date:  2018-12-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.